<DOC>
	<DOCNO>NCT01604187</DOCNO>
	<brief_summary>Colonoscopy generally consider invasive procedure cause remarkable pain patient . The pain associated procedure cause insertion scope inflate colon order inspection . It show colonoscopy perform successfully without sedation ( Leung , 2010 ) , many patient feel discomfort procedure . Factors predict painful colonoscopy female-gender , degree patient nervousness technical difficulty colonoscopy ( Ylinen et al . 2009 ) . Also age 40 , previous abdominal surgery use sedation associate painful colonoscopy ( Seip et al . 2009 ) . Most often sedation and/or analgesia achieve administering benzodiazepine combination benzodiazepine opioid ( Fanti et al . 2009 , Maskelar et al . 2009 , ) , dexmedetomidine ( Dere et al . 2009 ) use non-pharmacologic method ( Amer-Cuenca et al . 2011 ) . Tramadol monotherapy significantly decrease pain intensity endoscopist 's evaluation colonoscopy ( Grossi et al . 2004 ) . Currently , intravenous midazolam drug use commonly introduce sedation colonoscopy . Intravenous sedation definitely increase cost procedure ; drug administration , need pulse oximetry monitor need follow-up procedure make colonoscopy sometimes expensive troublesome . It also show , low-dose midazolam neither relief discomfort make patient forget ( Elphick et al . 2009 ) . Fentanyl short-acting opioid widely use anesthesia management . Transmucosal sublingual formulation fentanyl develop improve management pain . When administered sublingual fast-dissolving tablet ( Abstral® ) place tongue , effect fast predictable . Its active ingredient absorb body mucous membrane . After administration buccal fentanyl maximum plasma drug concentration measure 25 minute ( Darwish et al . 2011 ) . Plasma fentanyl concentration versus time follow buccal sublingual administration similar ( Darwish et al . 2008 ) . Abstral® sublingual tablet administer directly tongue deep part . Sublingual administration easy non-invasive method pain treatment patient come colonoscopy do office base procedure . Other advantage compare invasive method improve comfort patient need intravenous access pain relief . Before , use management breakthrough pain cancer patient . Sublingual fentanyl show effective well-tolerated treatment breakthrough cancer pain ( Uberall et al . 2011 ) . The use transmucosal tablet colonoscopy patient quite new approach .</brief_summary>
	<brief_title>Procedural Pain Treatment With Transmucosal Sublingual Fentanyl Tablet Colonoscopy Patients</brief_title>
	<detailed_description>The purpose study evaluate efficacy fentanyl transmucosal tablet placebo patient colonoscopy . Fentanyl highly lipophilic drug absorb rapidly oral mucosa slowly gastrointestinal tract . Orally administer fentanyl undergoes pronounce hepatic intestinal first pas effect . Abstral® quick dissolve sublingual tablet formulation . Rapid absorption fentanyl occur 30 minute follow administration Abstral® . The bioavailability Abstral® study estimate 70 % . Mean maximal plasma concentration fentanyl range 0.2 1.3 ng/ml ( administration 100 800 µg Abstral® ) reach within 22.5 240 minute . Fentanyl metabolise primarily via CYP3A4 number pharmacologically inactive metabolite , include norfentanyl . Within 72 hour intravenous fentanyl administration around 75 % dose excrete urine , mostly metabolites , less 10 % unchanged drug . About 9 % dose recover faeces , primarily metabolites . Total plasma clearance fentanyl 0.5 l/h/kg . After Abstral® administration , main elimination half-life fentanyl 7 hour ( range 3-12.5 hour ) terminal half-life 20 hour ( range 11.5-25 hour ) . Impaired hepatic renal function could cause increase serum concentration . Elderly , cachectic generally impaired patient may lower fentanyl clearance , could cause long terminal half-life compound . This randomized control double-blind study . A total 200 patient include . The patient recruit 18-85 year old male female patient undergoing colonoscopy . In view previous study ( Amer-Cuenca et al . 2011 ) calculate 87 patient need per group demonstrate 30 % decrease worst experience pain level significance P = 0.05 power 90 % . Because possible dropout , 100 patient recruited group . Pain assess numeral rating scale ( NRS ) . For calculation sample size , coefficient variation assume 70 % group .</detailed_description>
	<mesh_term>Fentanyl</mesh_term>
	<criteria>ASA IIII Colonoscopy Written inform consent participate subject A previous history intolerance study drug relate compound additive History alcoholism , drug abuse , psychiatric , psychological emotional problem likely invalidate inform consent Sleep apnoea Chronic obstructive pulmonary disease BMI ≥ 35 weight &lt; 50 kg SpO2 &lt; 90 % Concomitant drug therapy know cause significant enzyme induction inhibition CYP 3A4 . Pregnancy nursing .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>sublingual fentanyl</keyword>
	<keyword>pain coloscopy</keyword>
	<keyword>The efficacy safety fentanyl transmucosal tablet placebo patient colonoscopy .</keyword>
</DOC>